The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial

This study has suspended participant recruitment.
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
TEI Biosciences Inc. Identifier:
First received: October 25, 2010
Last updated: May 5, 2014
Last verified: May 2014

The primary aim of this study proposal is to test an innovative form of fetal bovine dermis bioscaffold in combination with negative pressure wound therapy (NPWT) to enhance wound healing in diabetic foot ulcers.

Condition Intervention
Foot Ulcer, Diabetic
Device: PriMatrix

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial

Resource links provided by NLM:

Further study details as provided by TEI Biosciences Inc.:

Primary Outcome Measures:
  • Time to healing [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2008
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental Arm (Internal Control)

One-half of ulcer receives negative pressure wound therapy

One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy

Device: PriMatrix
Dermal Repair Scaffold


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult Type 1 or 2 diabetic patients that present with foot ulcers.
  • Ulcer size of at least 3 centimeters (cm) in diameter at its widest dimension.
  • Ulcer depth: Full thickness (absence of all epithelial layers or deeper)
  • Adequate perfusion (at least one palpable pedal pulse or pedal bypass graft)
  • All ulcer durations will be eligible
  • Patients currently receiving NPWT for a diabetic foot ulcer
  • Patients must be appropriate NPWT candidates and be willing and able to sleep, ambulate, and rest with the NPWT unit in place.

Exclusion Criteria:

  • Active foot infections
  • Presence of any serious disease including end-stage renal failure requiring dialysis or renal transplantation or active malignant disease requiring treatment which seriously compromises the patient's ability to complete this study
  • Patients who are pregnant
  • Allergies to any material contained within the NPWT or bioscaffold
  • Any condition that would exclude NPWT use including but not limited to active bleeding, presence of malignancy in the wound or inability to follow any of the NPWT safety guidelines
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01228500

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Sponsors and Collaborators
TEI Biosciences Inc.
Beth Israel Deaconess Medical Center
Principal Investigator: Jeremy Cook, DPM Beth Israel Deaconess Medical Center, Harvard Medical School
  More Information

No publications provided

Responsible Party: TEI Biosciences Inc. Identifier: NCT01228500     History of Changes
Other Study ID Numbers: TEI-001
Study First Received: October 25, 2010
Last Updated: May 5, 2014
Health Authority: United States: Institutional Review Board processed this record on March 26, 2015